Published in Hepatology on July 02, 2012
Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Intern Med (2016) 1.77
Pathobiology of liver fibrosis: a translational success story. Gut (2015) 1.72
25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol (2013) 1.35
Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res (2014) 1.17
The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therap Adv Gastroenterol (2015) 0.97
Interferon-free combination therapies for the treatment of hepatitis C: current insights. Hepat Med (2015) 0.97
Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy. Int J Mol Sci (2015) 0.95
Sustained virological response: a milestone in the treatment of chronic hepatitis C. World J Gastroenterol (2013) 0.92
Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J Hepatol (2015) 0.87
The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent. Int J Mol Sci (2014) 0.85
Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. Hepatology (2015) 0.85
Noninvasive diagnosis of cirrhosis: a review of different imaging modalities. World J Gastroenterol (2014) 0.83
Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response. PLoS One (2017) 0.83
Altered quality of life in the early stages of chronic hepatitis C is due to the virus itself. Clin Res Hepatol Gastroenterol (2013) 0.81
Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality. World J Gastroenterol (2014) 0.80
Frontiers in the treatment of hepatitis C virus infection. Gastroenterol Hepatol (N Y) (2014) 0.79
Epithelial VEGF signaling is required in the mouse liver for proper sinusoid endothelial cell identity and hepatocyte zonation in vivo. Am J Physiol Gastrointest Liver Physiol (2014) 0.78
Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C. World J Gastroenterol (2015) 0.78
Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients. Biomed Res Int (2013) 0.78
Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care. Medicine (Baltimore) (2016) 0.77
Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease. F1000Res (2016) 0.76
New Concepts on Pathogenesis and Diagnosis of Liver Fibrosis; A Review Article. Middle East J Dig Dis (2016) 0.75
Slower Fibrosis Progression Among Liver Transplant Recipients With Sustained Virological Response After Hepatitis C Treatment. Gastroenterology Res (2015) 0.75
A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. Iran Red Crescent Med J (2016) 0.75
Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis. Hepatology (2017) 0.75
Oxidative stress, a trigger of hepatitis C and B virus-induced liver carcinogenesis. Oncotarget (2016) 0.75
Liver Stiffness Decreases Rapidly in Response to Successful Hepatitis C Treatment and Then Plateaus. PLoS One (2016) 0.75
Future therapy of portal hypertension in liver cirrhosis - a guess. F1000Prime Rep (2014) 0.75
Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon. PLoS One (2016) 0.75
Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World J Hepatol (2017) 0.75
Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol (2017) 0.75
Successful Interferon Therapy Reverses Enhanced Hepatic Progenitor Cell Activation in Patients with Chronic Hepatitis C. J Interferon Cytokine Res (2015) 0.75
Future complications of chronic hepatitis C in a low-risk area: projections from the hepatitis c study in Northern Norway. BMC Infect Dis (2017) 0.75
No significant impact of Foxf1 siRNA treatment in acute and chronic CCl4 liver injury. Exp Biol Med (Maywood) (2017) 0.75
Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med (2002) 10.78
Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology (2003) 10.25
The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut (2009) 6.50
Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology (2011) 4.60
Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology (2007) 3.73
Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology (2007) 3.61
Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut (2007) 3.58
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet (2010) 3.15
IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology (2012) 3.12
Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes (2006) 3.06
Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology (2009) 2.97
Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology (2004) 2.91
A comparison of fibrosis progression in chronic liver diseases. J Hepatol (2003) 2.82
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis. J Hepatol (2011) 2.78
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology (2003) 2.64
Sources of variability in histological scoring of chronic viral hepatitis. Hepatology (2005) 2.64
Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol (2010) 2.57
Fibrosis in human adipose tissue: composition, distribution, and link with lipid metabolism and fat mass loss. Diabetes (2010) 2.46
Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol (2010) 2.43
Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology (2006) 2.38
Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma. Hepatology (2011) 2.36
The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology (2006) 2.35
Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology (2009) 2.33
Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol (2004) 2.30
Changing trends in malignant transformation of hepatocellular adenoma. Gut (2011) 2.28
Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis. J Hepatol (2013) 2.23
Adipose tissue transcriptomic signature highlights the pathological relevance of extracellular matrix in human obesity. Genome Biol (2008) 2.22
Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection. J Hepatol (2013) 2.19
Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int (2008) 2.19
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology (2013) 2.13
Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication? Liver Int (2014) 2.09
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl (2007) 2.08
Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: the importance of tumor cell differentiation. Hepatology (2010) 2.06
Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology (2007) 2.03
The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol (2008) 2.03
Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology (2009) 2.00
Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology (2006) 1.97
IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol (2011) 1.97
Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology (2008) 1.95
Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatol (2011) 1.94
Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology (2006) 1.92
A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol (2013) 1.84
A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol (2007) 1.83
CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients. Eur J Immunol (2011) 1.81
Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study. Hepatology (2007) 1.81
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology (2009) 1.79
Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology (2003) 1.78
Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology (2011) 1.71
Risk factors of fibrosis in alcohol-induced liver disease. Hepatology (2002) 1.70
Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology (2011) 1.70
A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology (2009) 1.70
Abnormal plasma microparticles impair vasoconstrictor responses in patients with cirrhosis. Gastroenterology (2012) 1.69
Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl (2005) 1.68
Hepatitis C treatment in patients with kidney disease. Kidney Int (2013) 1.65
Liver biopsy: the best, not the gold standard. J Hepatol (2008) 1.65
Beyond "cirrhosis": a proposal from the International Liver Pathology Study Group. Am J Clin Pathol (2012) 1.65
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut (2012) 1.62
Segmental transcatheter arterial chemoembolization treatment in patients with cirrhosis and inoperable hepatocellular carcinomas. J Vasc Interv Radiol (2002) 1.62
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology (2005) 1.57
Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. Liver Int (2013) 1.57
Effects and regulation of connective tissue growth factor on hepatic stellate cells. Lab Invest (2002) 1.54
C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. J Hepatol (2011) 1.54
Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology (2005) 1.54
An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology (2009) 1.54
Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Virology (2005) 1.52
Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology (2012) 1.52
Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. Radiology (2008) 1.51
Cullin7: a new gene involved in liver carcinogenesis related to metabolic syndrome. Gut (2012) 1.50
Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology (2012) 1.49
Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology (2005) 1.48
Transient elastography assessment of the liver stiffness dynamics during acute hepatitis B. Eur J Gastroenterol Hepatol (2010) 1.47
Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin Endocrinol Metab (2010) 1.44
In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C. J Pathol (2010) 1.41
Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology (2011) 1.40
Long-term results of renal transplantation using kidneys harvested from non-heartbeating donors: a 15-year experience. J Urol (2003) 1.39
Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol (2010) 1.38
Acute liver cell damage in patients with anorexia nervosa: a possible role of starvation-induced hepatocyte autophagy. Gastroenterology (2008) 1.34